Jiangsu Hengrui Pharmaceuticals Co Ltd Class A 600276
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Novo Nordisk strikes second licensing deal since frosty capital-markets day
-
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
-
Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
-
Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI
-
Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up
Trading Information
- Previous Close Price
- CN¥45.62
- Day Range
- CN¥45.25–47.39
- 52-Week Range
- CN¥41.89–71.66
- Bid/Ask
- CN¥47.20 / CN¥47.21
- Shares Outstanding
- 6.64B
- Market Cap
- CN¥313.28B
- Volume/Avg
- 112M / 87M
Key Statistics
- Price/Earnings (Normalized)
- 40.70
- Price/Sales
- 10.00
- Dividend Yield (Trailing)
- 0.42%
- Dividend Yield (Forward)
- 0.42%
- Dividend Payment Schedule
- May
- Total Yield
- 0.42%
Company Profile
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 20,602
- Website
- https://www.hengrui.com
Valuation
|
Metric
|
600276
|
|---|---|
Price/Earnings (Normalized) | 40.70 |
Price/Book Value | 4.86 |
Price/Sales | 10.00 |
Price/Cash Flow | 34.00 |
Price/Earnings
600276
Financial Strength
|
Metric
|
600276
|
|---|---|
Quick Ratio | 10.62 |
Current Ratio | 11.68 |
Interest Coverage | 1,298.64 |
Quick Ratio
600276
Profitability
|
Metric
|
600276
|
|---|---|
Return on Assets (Normalized) | 10.13% |
Return on Equity (Normalized) | 11.19% |
Return on Invested Capital (Normalized) | 9.30% |
Return on Assets
600276
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|Wb<v^Yrk | LOCK|VT#%p | $67B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|P>gB!W?f | LOCK|Rgjx | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|!JxL?@ | LOCK|%@< | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|B#s>l@Zl | LOCK|>$d | $29B | |||
| Viatris Inc
VTRS
| LOCK|pF$P?W | LOCK|?SF | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|#%< | LOCK|VP | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|^$$?Z!? | LOCK|y!$ | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|HszR?t? | LOCK|SY | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|B#zt%vB | LOCK|lLw@ | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|lgF?Jg | LOCK|d!> | $2B |
United States